Mainstay Medical looks to raise up to $42 million with an initial public offering on the EuroNext stock exchange.
Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.
Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1mhl0wI
Cap comentari:
Publica un comentari a l'entrada